OBSERVATIONAL STUDY OF CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) TREATED BY THROMBOPOIETIN RECEPTOR AGONISTS (TPO-R) IN FRANCE

Trial description: Immune thrombocytopenia, previously called Immune thrombocytopenic purpura (ITP), is an autoimmune coagulation disorder characterised by isolated thrombocytopenia (platelet count < 150 x 109/L).The annual incidence in Europe is estimated to be between 2.68 and 3.9 per 100,000 person-years and the prevalence in France is 25/100,000. ITP is classed into three categories according to the duration and course of the disease: 1/ newly diagnosed ITP, of not more than three months in duration, 2/ persistent ITP (3 to 12 months) and 3/ chronic ITP (lasting for more than 12 months). Medication is only indicated for patients with a platelet count < 30 x 109/L, though the best strategy is still controversial and primary therapy must be individually tailored for each patient. First-line treatments are corticosteroids and intravenous immunoglobulins (IVIg) which only have transient efficacy. Splenectomy represents the reference surgical treatment for Chronic ITP. After splenectomy or when surgery is contraindicated second-line drug therapy may be proposed to patients: corticosteroids in combination with IVIg, Rituximab or TPO receptor agonists. The purpose of the SATURNE observational study is to obtain epidemiological data about real-life use of TPO receptor agonists and their place in the management of adult patients with chronic ITP.